These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21343468)

  • 1. Integrase inhibitors effective against human T-cell leukemia virus type 1.
    Seegulam ME; Ratner L
    Antimicrob Agents Chemother; 2011 May; 55(5):2011-7. PubMed ID: 21343468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication.
    Rabaaoui S; Zouhiri F; Lançon A; Leh H; d'Angelo J; Wattel E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3532-41. PubMed ID: 18316517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 4. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.
    Goffinet C; Allespach I; Oberbremer L; Golden PL; Foster SA; Johns BA; Weatherhead JG; Novick SJ; Chiswell KE; Garvey EP; Keppler OT
    J Virol; 2009 Aug; 83(15):7706-17. PubMed ID: 19458008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the HIV integration process in antiviral therapy.
    McNeely M; Christ F; Thys W; Debyser Z
    J HIV Ther; 2008 Dec; 13(4):83-92. PubMed ID: 19418658
    [No Abstract]   [Full Text] [Related]  

  • 7. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
    Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.
    Cooper A; García M; Petrovas C; Yamamoto T; Koup RA; Nabel GJ
    Nature; 2013 Jun; 498(7454):376-9. PubMed ID: 23739328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].
    Mirambeau G
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():11-6. PubMed ID: 19572420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
    Beare KD; Coster MJ; Rutledge PJ
    Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir.
    Beck-Engeser GB; Eilat D; Harrer T; Jäck HM; Wabl M
    Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20865-70. PubMed ID: 19923437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tools to track HIV.
    Schacker T
    Nat Med; 2010 Apr; 16(4):373-4. PubMed ID: 20376041
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
    Hazuda D; Iwamoto M; Wenning L
    Annu Rev Pharmacol Toxicol; 2009; 49():377-94. PubMed ID: 18928385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
    Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
    Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to inhibitors of the human immunodeficiency virus type 1 integration.
    Hazuda DJ
    Braz J Infect Dis; 2010; 14(5):513-8. PubMed ID: 21221483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir: molecular basis of its mechanism of action.
    Mouscadet JF; Tchertanov L
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):5-16. PubMed ID: 19959411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.